Can-Fite BioPharma annual return on equity
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Can-Fite BioPharma Return on Equity (ROE) Growth & History (CANF)
Can-Fite BioPharma's return on equity was −178.24% for fiscal 2025.
View full Can-Fite BioPharma company overviewCan-Fite BioPharma annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −178.24% | −43.29 pp |
| 2024 | 2024-12-31 | −134.94% | +7.55 pp |
| 2023 | 2023-12-31 | −142.49% | −34.58 pp |
| 2022 | 2022-12-31 | −107.91% | +15.42 pp |
| 2021 | 2021-12-31 | −123.34% | +215.86 pp |
| 2020 | 2020-12-31 | −339.20% | +123.51 pp |
| 2019 | 2019-12-31 | −462.71% | −243.64 pp |
| 2018 | 2018-12-31 | −219.07% | −75.24 pp |
| 2017 | 2017-12-31 | −143.83% | −59.43 pp |
| 2016 | 2016-12-31 | −84.41% | — |
Can-Fite BioPharma return on equity trends
Over the last five fiscal years, Can-Fite BioPharma's return on equity increased from −339.20% to −178.24%, a change of +160.96 percentage points.
About the metric
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
Calculation and source
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Can-Fite BioPharma source filings ↗